MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.020
+0.083
+8.87%
After Hours: 1.020 0 0.00% 19:58 03/05 EST
OPEN
0.9901
PREV CLOSE
0.9369
HIGH
1.030
LOW
0.7695
VOLUME
42.44M
TURNOVER
--
52 WEEK HIGH
1.930
52 WEEK LOW
0.1901
MARKET CAP
213.74M
P/E (TTM)
-3.9969
1D
5D
1M
3M
1Y
5Y
Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results
GlobeNewswire · 2d ago
8-K: Onconova Therapeutics, Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Thinking about buying stock in Tanger Factory Outlet Centers, Onconova Therapeutics, Cinedigm, Cigna Corp, or Anthem?
NEW YORK, March 4, 2021 /PRNewswire via COMTEX/ -- NEW YORK, March 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SKT, ONTX,...
PR Newswire - PRF · 2d ago
Okta, Schrodinger leads the premarket losers' pack
Schrodinger (SDGR) -25% on Q4 earnings release.Purple Innovation (PRPL) -21% on Q4 earning release.Qutoutiao (QTT) -20% on Q4 earning release.Yext (YEXT) -19% on Q4 earning release.Vroom (VRM) -15% on Q4 earning release.KemPharm (KMPH) -13%.Salarius Pharma...
Seekingalpha · 2d ago
Anemia Drugs Market Demand Fuelled by Increased R and D Activities, Says Market.us
Mar 02, 2021 (WiredRelease via Comtex) -- A recent systematic review report on “Anemia Drugs Market is Expected to Thrive at Impressive CAGR by 2031 |...
marketresearch.biz · 4d ago
Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March
NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D....
GlobeNewswire · 5d ago
8-K: Onconova Therapeutics, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 00:11
4 Cheap Penny Stocks To Watch Under $3 Before March 2021
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are These Cheap Stocks On Your Watch List This Week? The markets are ablaze with upbeat sentiment, and penny stocks...
Penny Stocks · 02/24 21:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONTX. Analyze the recent business situations of Onconova through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONTX stock price target is 2.100 with a high estimate of 2.100 and a low estimate of 2.100.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 16.02M
% Owned: 7.64%
Shares Outstanding: 209.55M
TypeInstitutionsShares
Increased
7
2.09M
New
19
959.54K
Decreased
8
759.16K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer
Mark Guerin
Vice President/General Counsel
Abraham Oler
Director
Henry Bienen
Director
Jerome Groopman
Director
Viren Mehta
Director
Terri Shoemaker
Director
Jack Stover
Director
Anne VanLent
No Data
  • All
  • Financials
  • Insiders
More
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.